Dry Eye

Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.

Knowing pregnancy-related risks enhances patient safety.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.

Investigators noted the patient's symptoms "reliably abated when she played the oboe or when she sang, only to return immediately after stopping.”

NYU researchers discuss using CellChek C widefield specular microscopy to visualize and quantify corneal nerves in dry eye disease, revealing reduced nerve fiber length and inferior whorl changes and offering a practical alternative to in vivo confocal imaging.

Learn how IBD affects gut and beyond—risk factors, gender differences, eye complications, and treatment options to manage flares and protect vision.

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

Several presentations at ASCRS 2026 spotlight faster dry eye relief and smarter pre-operative care, showing lifitegrast and new drugs can ease symptoms quickly and improve cataract biometry.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

Previously, the company had received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED

Ophthalmologists report dry eye’s mixed mechanisms, symptom-driven diagnosis, uneven treatment response, and payer hurdles—what needs fixing next.

Interventional therapies give patients faster relief and better vision outcomes

Dry eye care shifts to spectrum-based screening and targeted therapies, from TRPM8 agonists to evaporation shields, with upcoming anti-inflammatories promising faster relief.

New research compares 7 HA dry eye drops; Ivizia and Thealoz Duo most closely match natural tear viscosity during blinking.

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

Optometrists track 2026 breakthroughs in dry eye therapies, AI-powered screening and referrals, and genetics-driven glaucoma risk tools that reshape patient care.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

An overview of the top 10 stories from Optometry Times in 2025.

Panel examines drug mechanisms, patient factors, and strategies to optimize results.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.